Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUM in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia
NCT03188172Phase 2Active, not recruiting
- Sponsor
- University of Leeds
- Start
- Sep 2017
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, lenalidomide, daratumumab, dexamethasone, cyclophosphamide in multiple myeloma (MM), plasma cell leukemia (PCL), sponsored by University of Leeds. Started Sep 2017; status: active, not recruiting.
02
Drugs
bortezomiblenalidomidedaratumumabdexamethasonecyclophosphamide
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT03188172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03188172.